The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments
Open accessAbstract
OBJECTIVE: To describe the potential benefits and harms of oseltamivir by reviewing all clinical study reports (or similar document when no clinical study report exists) of randomised placebo controlled trials and regulatory comments ("regulatory information"). DESIGN: Systematic review of regulatory information. DATA SOURCES: Clinical study reports, trial registries, electronic databases, regulatory archives, and correspondence with manufacturers. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised placebo controlled trials on adults and children who had confirmed or suspected exposure to natural influenza. MAIN OUTCOME MEASURES: Time to first alleviation of symptoms, influenza outcomes, complications, admissions to hospital, and adverse events in the intention to treat population. RESULTS: From the European Medicines Agency and Roche, we obtained clinical study reports for 83 trials. We included 23 trials in stage 1 (reliability and completeness screen) and 20 in stage 2 (formal analysis). In treatment trials on adults, oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours (95% confidence interval 8.4 to 25.1 hours, P<0.001). There was no effect in children with asthma, but there was an effect in otherwise healthy children (mean difference 29 hours, 95% confidence interval 12 to 47 hours, P=0.001). In treatment trials there was no difference in admissions to hospital in adults (risk difference 0.15%, 95% confidence interval -0.91% to 0.78%, P=0.84) and sparse data in children and for prophylaxis. In adult treatment trials, oseltamivir reduced investigator mediated unverified pneumonia (risk difference 1.00%, 0.22% to 1.49%; number needed to treat to benefit (NNTB) 100, 95% confidence interval 67 to 451). The effect was not statistically significant in the five trials that used a more detailed diagnostic form for "pneumonia," and no clinical study reports reported laboratory or diagnostic confirmation of "pneumonia." The effect on unverified pneumonia in children and for prophylaxis was not significant. There was no significant reduction in risk of unverified bronchitis, otitis media, sinusitis, or any complication classified as serious or that led to study withdrawal. 14 of 20 trials prompted participants to self report all secondary illnesses to an investigator. Oseltamivir in the treatment of adults increased the risk of nausea (risk difference 3.66%, 0.90% to 7.39%; number needed to treat to harm (NNTH) 28, 95% confidence interval 14 to 112) and vomiting (4.56%, 2.39% to 7.58%; 22, 14 to 42). In treatment of children, oseltamivir induced vomiting (5.34%, 1.75% to 10.29%; 19, 10 to 57). In prophylaxis trials, oseltamivir reduced symptomatic influenza in participants by 55% (3.05%, 1.83% to 3.88%; NNTB 33, 26 to 55) and households (13.6%, 9.52% to 15.47%; NNTB 7, 6 to 11) based on one study, but there was no significant effect on asymptomatic influenza and no evidence of a reduction in transmission. In prophylaxis studies, oseltamivir increased the risk of psychiatric adverse events during the combined "on-treatment" and "off-treatment" periods (risk difference 1.06%, 0.07% to 2.76%; NNTH 94, 36 to 1538) and there was a dose-response effect on psychiatric events in two "pivotal" treatment trials of oseltamivir, at 75 mg (standard dose) and 150 mg (high dose) twice daily (P=0.038). In prophylaxis studies, oseltamivir increased the risk of headaches on-treatment (risk difference 3.15%, 0.88% to 5.78%; NNTH 32, 18 to 115), renal events with treatment (0.67%, -0.01% to 2.93%), and nausea while receiving treatment (4.15%, 0.86% to 9.51%; NNTH 25, 11 to 116). CONCLUSIONS: In prophylactic studies oseltamivir reduces the proportion of symptomatic influenza. In treatment studies it also modestly reduces the time to first alleviation of symptoms, but it causes nausea and vomiting and increases the risk of headaches and renal and psychiatric syndromes. The evidence of clinically significant effects on complications and viral transmission is limited because of rarity of such events and problems with study design. The trade-off between benefits and harms should be borne in mind when making decisions to use oseltamivir for treatment, prophylaxis, or stockpiling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Dooley, L., Hama, R., & Heneghan, C. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001265.pub2 · Cited by 226
Self-citationRetractedCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Neuraminidase Inhibitors for Influenza
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050740 · Cited by 1,094
U.S. Department of Health and Human (2015) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2015.1037530 · Cited by 891
Containing Pandemic Influenza with Antiviral Agents
Longini, I. M. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh092 · Cited by 705
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Heneghan, C. J., Hama, R., & Thompson, M. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008965.pub3 · Cited by 594
Self-citationHrobjartsson, A., Thomsen, A. S. S., Emanuelsson, F., Tendal, B., Hilden, J., Boutron, I., Ravaud, P., & Brorson, S. (2012) · BMJ · doi:10.1136/bmj.e1119 · Cited by 483
Jefferson, T., Jones, M., Doshi, P., & Del Mar, C. (2009) · BMJ · doi:10.1136/bmj.b5106 · Cited by 363
Self-citationCooper, N. J., Sutton, A. J., Abrams, K. R., Wailoo, A., Turner, D., & Nicholson, K. G. (2003) · BMJ · doi:10.1136/bmj.326.7401.1235 · Cited by 357
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Hama, R., Thompson, M., Spencer, E. A., Onakpoya, I., Mahtani, K. R., Nunan, D. N., et al. (2014) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.20141324t2 · Cited by 319
Self-citationNeuraminidase inhibitors for preventing and treating influenza in children
Matheson, N. J., Harnden, A., Perera, R., Sheikh, A., & Symmonds-Abrahams, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002744.pub2 · Cited by 180
Shun-Shin, M., Thompson, M., Heneghan, C., Perera, R., Harnden, A., & Mant, D. (2009) · BMJ · doi:10.1136/bmj.b3172 · Cited by 167
Self-citationToovey, S., Rayner, C., Prinssen, E., Chu, T., Donner, B., Thakrar, B., Dutkowski, R., Hoffmann, G., Breidenbach, A., Lindemann, L., et al. (2008) · Drug Safety · doi:10.2165/0002018-200831120-00006 · Cited by 165
Does Influenza Transmission Occur from Asymptomatic Infection or Prior to Symptom Onset?
Patrozou, E., & Mermel, L. A. (2009) · Public Health Reports · doi:10.1177/003335490912400205 · Cited by 123
Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)
Wang, K., Shun-Shin, M. J., Gill, P. J., Perera, R., & Harnden, A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002744.pub4 · Cited by 89
Doshi, P., & Jefferson, T. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002496 · Cited by 88
Self-citationRespiratory Distress Associated with Zanamivir
Williamson, J., & Pegram, P. S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003023420914 · Cited by 66
Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Jefferson, T., Jones, M., Doshi, P., Mar, C. D., Dooley, L., & Foxlee, R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001265.pub3 · Cited by 62
Self-citationRethinking credible evidence synthesis
Doshi, P., Jones, M., & Jefferson, T. (2012) · BMJ · doi:10.1136/bmj.d7898 · Cited by 60
Self-citationClinical trial data for all drugs in current use
Godlee, F. (2012) · BMJ · doi:10.1136/bmj.e7304 · Cited by 57
Ensuring safe and effective drugs: who can do what it takes?
Jefferson, T., Doshi, P., Thompson, M., Heneghan, C. J., & C. A. R. I. Group (2011) · BMJ · doi:10.1136/bmj.c7258 · Cited by 43
Self-citationNeuropsychiatric Adverse Events and Oseltamivir for Prophylaxis
Jones, M., Hama, R., Jefferson, T., & Doshi, P. (2012) · Drug Safety · doi:10.1007/bf03262007 · Cited by 12
Self-citationZanamivir for influenza: a public health perspective
Nguyen‐Van‐Tam, J. S. (1999) · BMJ · doi:10.1136/bmj.319.7211.655 · Cited by 9
Toovey, S. (2012) · Drug Safety · doi:10.2165/11641700-000000000-00000 · Cited by 3
Cited by
Guo (2020) · doi:10.1186/s40779-020-00240-0 · Cited by 4,735
The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta‐analyses
IOANNIDIS, J. P. A. (2016) · The Milbank Quarterly · doi:10.1111/1468-0009.12210 · Cited by 1,483
Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy866 · Cited by 795
Paules, C., & Subbarao, K. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30129-0 · Cited by 740
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials
Dobson, J., Whitley, R. J., Pocock, S., & Monto, A. S. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62449-1 · Cited by 594
Metadata
- Authors
- Jefferson, T., Jones, M., Doshi, P., Spencer, E. A., Onakpoya, I., & Heneghan, C. J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2014-04-09
- Volume
- 348
- Issue
- apr09 2
- Pages
- g2545-g2545
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W2091139031
- Cited by
- 447
- References
- 24
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.